Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: Infect Control Hosp Epidemiol. 2015 Jan;36(1):2–13. doi: 10.1017/ice.2014.1

Figure 1.

Figure 1

Cost-Benefit model structure. Patients enter the model as MRSA colonized at each pre-specified body site or not colonized. MRSA colonized patients are detected based on the sensitivity and specificity determined from the literature. Costs and benefits are allocated based on results of the screening tests and benefit of contact precautions.

CP= contact precautions; MRSA = Methicillin-resistant Staphylococcus aureus; “True” negative = An MRSA carrier is not detected because the wrong site was chosen for surveillance, e.g. a patient colonized in the groin only who undergoes nares-only surveillance.